CAMBRIDGE, Mass., Jan. 31, 2017 /PRNewswire-iReach/ -- John Adamou has joined DNA Medicine Institute, Inc. and its spin-off rHEALTH LLC, as Vice President of Corporate and Business Development and a member of the founding Senior Management team.
“We are thrilled to have someone of John’s caliber and experience join us in advancing our mission of empowering our health with point-of-patient health solutions,” said Dr. Eugene Chan, Founder and CEO.
Mr. Adamou has over 20 years of business development, strategic transactions, and scientific experience in the pharmaceutical and biotechnology industries. He spent fifteen years with Boehringer Ingelheim Pharmaceuticals as Head of Strategic Transactions and Alliance Management located in Ridgefield, Connecticut. In that role, he led a transaction team responsible for structuring, negotiating and managing global partnerships. He has an established track-record and experience with a broad array of deal structures across various therapeutic categories including digital health innovation (personally involved in more than 75 strategic transactions, including platform technologies, R&D collaborations, co-development and co-commercialization alliances, IP licenses, equity investments, and out-licensing initiatives). Before Boehringer Ingelheim, Mr. Adamou began his business development career in 2000 at MedImmune. Earlier in his career, Mr. Adamou held various research roles of increasing responsibility with MedImmune, SmithKline Beecham Pharmaceuticals, and Allelix Biopharmaceuticals.
“I am delighted to be part of this unique opportunity to increase healthcare accessibility for patients. I will leverage my experience in global partnering to help bring the rHEALTH technology to patients,” said John.
Mr. Adamou holds BS and MS degrees in Molecular Biology and Genetics from the University of Guelph, Canada, and an MBA from Keller Graduate School of Management.
About rHEALTH
rHEALTH is a digital health solutions company focused on creating integrated technologies that fundamentally change how we care for our health. rHEALTH’s innovations consists of the rHEALTH diagnostic platform, which enables diverse laboratory test classes in a single small volume blood sample, the SKYE Sensor, a wireless wearable providing comprehensive real-time vitals monitoring and CHAS, a user-friendly mobile application. For more information, please visit www.rhealth.com.
About DNA Medicine Institute
DNA Medicine Institute (DMI) is a biomedical incubator focused on advancing patient care, alleviating human suffering, and treating disease through innovation. Its work is supported by NASA, National Institutes of Health, and the Bill & Melinda Gates Foundation. DMI leverages substantial expertise in interdisciplinary science and engineering to solve challenging problems. For more information, visit www.dnamedinstitute.com.
Media Contact:Lillian Li, rHEALTH LLC, (617) 913-7630, pr@rhealth.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE rHEALTH LLC
